Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma.

IF 3.8 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Expert Review of Gastroenterology & Hepatology Pub Date : 2024-10-01 Epub Date: 2024-10-22 DOI:10.1080/17474124.2024.2419519

Bernardo Stefanini, Giulia F Manfredi, Antonio D'Alessio, Claudia A M Fulgenzi, Nichola Awosika, Ciro Celsa, Mario Pirisi, Cristina Rigamonti, Michela Burlone, Federica Vincenzi, Rosalba Minisini, Alessandra Gennari, Vincent Yip, Sarah Slater, Karim El-Shakankery, Ananya Jain, Francesco Tovoli, Fabio Piscaglia, Duncan Spalding, Madhava Pai, David J Pinato

{"title":"Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma.","authors":"Bernardo Stefanini, Giulia F Manfredi, Antonio D'Alessio, Claudia A M Fulgenzi, Nichola Awosika, Ciro Celsa, Mario Pirisi, Cristina Rigamonti, Michela Burlone, Federica Vincenzi, Rosalba Minisini, Alessandra Gennari, Vincent Yip, Sarah Slater, Karim El-Shakankery, Ananya Jain, Francesco Tovoli, Fabio Piscaglia, Duncan Spalding, Madhava Pai, David J Pinato","doi":"10.1080/17474124.2024.2419519","DOIUrl":null,"url":null,"abstract":"Introduction: Hepatocellular carcinoma (HCC) presents a formidable challenge in oncology, demanding innovative treatment approaches. Both adjuvant and neoadjuvant therapies, thanks to the introduction of immunotherapy, have emerged as promising strategies in the management of HCC, aiming to reduce the risk of relapse and ultimately to improve survival.Areas covered: This review considers current evidence, ongoing clinical trials, and future strategies to elucidate the evolving landscape of neoadjuvant and adjuvant treatments in HCC.Expert opinion: Both adjuvant and neoadjuvant regimens, notably those incorporating immune checkpoint inhibitors, demonstrated encouraging safety profiles and efficacy outcomes in HCC.While significant challenges persist, including optimizing patient selection and endpoint definition, the evolving landscape of neoadjuvant and adjuvant therapy holds promise for maximizing the therapeutic potential of immunotherapy across all stages of HCC. Further insights into tumor biology and host immunity will shape the role of these approaches which are close to becoming reality in clinical practice.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"647-660"},"PeriodicalIF":3.8000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474124.2024.2419519","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Hepatocellular carcinoma (HCC) presents a formidable challenge in oncology, demanding innovative treatment approaches. Both adjuvant and neoadjuvant therapies, thanks to the introduction of immunotherapy, have emerged as promising strategies in the management of HCC, aiming to reduce the risk of relapse and ultimately to improve survival.

Areas covered: This review considers current evidence, ongoing clinical trials, and future strategies to elucidate the evolving landscape of neoadjuvant and adjuvant treatments in HCC.

Expert opinion: Both adjuvant and neoadjuvant regimens, notably those incorporating immune checkpoint inhibitors, demonstrated encouraging safety profiles and efficacy outcomes in HCC.While significant challenges persist, including optimizing patient selection and endpoint definition, the evolving landscape of neoadjuvant and adjuvant therapy holds promise for maximizing the therapeutic potential of immunotherapy across all stages of HCC. Further insights into tumor biology and host immunity will shape the role of these approaches which are close to becoming reality in clinical practice.

查看原文本刊更多论文

在肝细胞癌早期阶段提供辅助治疗和新辅助治疗。

简介肝细胞癌（HCC）是肿瘤学领域的一项严峻挑战，需要创新的治疗方法。由于免疫疗法的引入，辅助疗法和新辅助疗法已成为治疗 HCC 的有效策略，旨在降低复发风险并最终提高生存率：本综述考虑了当前的证据、正在进行的临床试验和未来的策略，以阐明HCC新辅助治疗和辅助治疗不断发展的前景：虽然仍存在重大挑战，包括优化患者选择和终点定义，但新辅助治疗和辅助治疗的不断发展有望最大限度地发挥免疫疗法在HCC各阶段的治疗潜力。对肿瘤生物学和宿主免疫的进一步了解将决定这些方法的作用，它们即将成为临床实践中的现实。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Gastroenterology & Hepatology GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

6.80

自引率

2.60%

发文量

审稿时长

6-12 weeks

期刊介绍： The enormous health and economic burden of gastrointestinal disease worldwide warrants a sharp focus on the etiology, epidemiology, prevention, diagnosis, treatment and development of new therapies. By the end of the last century we had seen enormous advances, both in technologies to visualize disease and in curative therapies in areas such as gastric ulcer, with the advent first of the H2-antagonists and then the proton pump inhibitors - clear examples of how advances in medicine can massively benefit the patient. Nevertheless, specialists face ongoing challenges from a wide array of diseases of diverse etiology.